✦ LIBER ✦

A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck : Southwest Oncology Group study 0007

✍ Scribed by Francis P. Worden; James Moon; Wolfram Samlowski; Joseph I. Clark; Shaker R. Dakhil; Stephen Williamson; Susan G. Urba; John Ensley; Maha H. Hussain;; Southwest Oncology Group; the Head; Neck Working Group

Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 127 KB
Volume: 107
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.21994

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Paclitaxel, cisplatin, and 5-fluorouraci

Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck

✍ Maha Hussain; Shirish Gadgeel; Omer Kucuk; Wei Du; Walter Salwen; John Ensley 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB 👁 3 views

## BACKGROUND. The combination of cisplatin and 5-flurouracil (5-FU) is considered standard therapy for patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Paclitaxel has exhibited single-agent activity in patients with this disease. The authors conducted thi

Evaluation of 96-hour infusion fluoroura

Evaluation of 96-hour infusion fluorouracil plus cisplatin in combination with alpha interferon for patients with advanced squamous cell carcinoma of the head and neck. A southwest oncology group study

✍ Maha Hussain; Jacqueline Benedetti; Roy E. Smith; Gladys I. Rodriguez; David Sch 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 456 KB 👁 2 views

Evaluation of low dose continuous infusi

Evaluation of low dose continuous infusion 5-fluorouracil in patients with advanced and recurrent renal cell carcinoma. A Southwest Oncology Group study

✍ Julie A. Kish; Michael Wolf; E. David Crawford; Joseph T. Leimert; Anton Buesche 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 289 KB 👁 2 views

Background. The response rate of metastatic renal cell cancer to cytotoxic therapy over the last 10 years has been 5.6%. Low dose continuous 5-fluorouracil(5-FU) has demonstrated efficacy in other cytotoxic refractory tumors, such as pancreas, colorectal, and recurrent breast. The Southwest Oncology

Cisplatin and 5-fluorouracil chemotherap

Cisplatin and 5-fluorouracil chemotherapy in advanced or recurrent squamous cell carcinoma of the head and neck

✍ Richard J. Mercier; G. David Neal; Douglas E. Mattox; George A. Gates; Thomas C. 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 404 KB 👁 2 views

A phase II trial of interferon-α and 5-f

A phase II trial of interferon-α and 5-fluorouracil in patients with advanced renal cell carcinoma: A Southwest Oncology Group study

✍ Laurence Elias; Brent A. Blumenstein; Julie Kish; Robert C. Flanigan; James L. W 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 355 KB 👁 1 views

## BACKGROUND. Renal cell carcinoma is a common neoplasm that is often refractory to treatment. It is occasionally responsive to immunoniodulating agents including interferon-a, which enhances the effects of 5-fluorouracil upon cells. Combinations of these two drugs have been most frequently tested

A phase II trial of cisplatin and vinore

A phase II trial of cisplatin and vinorelbine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

✍ Enrique Espinosa; Pilar Zamora; Alfredo Millá; Serafin Morales; Raquel Molina; M 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 75 KB 👁 2 views

## Abstract ## Objective. We assessed the response rate and the toxicity of cisplatin plus vinorelbine in patients with this condition. ## Patients and Method. Forty‐two patients were included. Therapy consisted of cisplatin, 100 mg/m^2^ on day 1, and vinorelbine, 25 mg/m^2^ on days 1 and 8, giv